Immatics (IMTX) Operating Expenses (2019 - 2026)
Immatics (IMTX) posted Operating Expenses of $1.4 billion for Q4 2025, up 2119.8% sequentially from -$70.0 million in Q3 2025, and up 305.06% YoY from $348.9 million in Q4 2024.
Analysis
Immatics (IMTX) Operating Expenses (2019 - 2026) Analysis & Trends
Immatics has reported Operating Expenses for 7 years, with the latest figure at $1.4 billion in Q4 2025.
- Quarterly Operating Expenses rose 305.06% year-over-year to $1.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 245.26% YoY) and the FY2025 annual result came in at $1.2 billion, up 238.77% from the prior year.
- Operating Expenses improved to $1.4 billion in Q4 2025 per IMTX's latest filing, from -$70.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $1.4 billion in Q4 2025 and troughed at -$689.2 million in Q4 2024.
- A 5-year average of $108.9 million and a median of -$39.3 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2021 and 2024: Operating Expenses jumped 1832.07% in 2021, then tumbled 182.17% in 2024.
- Over 5 years, Operating Expenses stood at $610.2 million in 2021, then climbed by 13.13% to $690.3 million in 2022, then climbed by 21.5% to $838.7 million in 2023, then plunged by 182.17% to -$689.2 million in 2024, then surged by 305.06% to $1.4 billion in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.4 billion, -$70.0 million, and -$65.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -88.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -88.74 Mn |
| Mar 31, 2026 | -86.28 Mn |
| Dec 31, 2025 | -73.69 Mn |
| Sep 30, 2025 | -69.97 Mn |
| Jun 30, 2025 | -65.52 Mn |
| Mar 31, 2025 | -56.78 Mn |
| Dec 31, 2024 | -59.17 Mn |
| Sep 30, 2024 | -54.98 Mn |
| Jun 30, 2024 | -48.83 Mn |
| Mar 31, 2024 | -47.53 Mn |
| Dec 31, 2023 | -46.95 Mn |
| Sep 30, 2023 | -42.87 Mn |
| Jun 30, 2023 | -39.94 Mn |
| Mar 31, 2023 | -39.89 Mn |
| Dec 31, 2022 | -38.35 Mn |
| Sep 30, 2022 | -37.30 Mn |
| Jun 30, 2022 | -36.17 Mn |
| Mar 31, 2022 | -38.63 Mn |
| Dec 31, 2021 | -36.38 Mn |
| Sep 30, 2021 | -34.78 Mn |